- Home
- HQL vs OMER Comparison
HQL vs OMER Comparison
Compare HQL & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQL
- OMER
- Stock Information
- Founded
- HQL 1992
- OMER 1994
- Country
- HQL United States
- OMER United States
- Employees
- HQL N/A
- OMER N/A
- Industry
- HQL Investment Managers
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- HQL Finance
- OMER Health Care
- Exchange
- HQL Nasdaq
- OMER Nasdaq
- Market Cap
- HQL 368.7M
- OMER 397.1M
- IPO Year
- HQL N/A
- OMER 2009
- Fundamental
- Price
- HQL $12.24
- OMER $3.09
- Analyst Decision
- HQL
- OMER Buy
- Analyst Count
- HQL 0
- OMER 4
- Target Price
- HQL N/A
- OMER $22.50
- AVG Volume (30 Days)
- HQL 120.9K
- OMER 1.4M
- Earning Date
- HQL 01-01-0001
- OMER 05-15-2025
- Dividend Yield
- HQL 11.56%
- OMER N/A
- EPS Growth
- HQL N/A
- OMER N/A
- EPS
- HQL 0.79
- OMER N/A
- Revenue
- HQL N/A
- OMER N/A
- Revenue This Year
- HQL N/A
- OMER N/A
- Revenue Next Year
- HQL N/A
- OMER $2,447.88
- P/E Ratio
- HQL $17.08
- OMER N/A
- Revenue Growth
- HQL N/A
- OMER N/A
- 52 Week Low
- HQL $11.34
- OMER $2.97
- 52 Week High
- HQL $14.37
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- HQL 48.22
- OMER 26.94
- Support Level
- HQL $12.18
- OMER $3.00
- Resistance Level
- HQL $12.53
- OMER $3.34
- Average True Range (ATR)
- HQL 0.25
- OMER 0.49
- MACD
- HQL -0.00
- OMER -0.00
- Stochastic Oscillator
- HQL 39.51
- OMER 4.10
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.